Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

Webcasts


Play
ODYSSEY OUTCOMES: Update
Play
New data from FOURIER and design of the VESALIUS-CV Trial
Play
PCSK9 Genetics: New Insights
Play Hepatic lipid metabolism: Storage vs secretion
Jan Boren Hepatic lipid metabolism: Storage vs secretion
Play Using naturally randomized genetic evidence to estimate the clinical benefit of lowering triglyceride-rich lipoproteins
Using naturally randomized genetic evidence to estimate the clinical benefit of lowering triglyceride-rich lipoproteins
Play New approaches to treatment of moderate hypertriglyceridemia and new therapeutic combinations
Erik Stroes New approaches to treatment of moderate hypertriglyceridemia and new therapeutic combinations
Play Inclisiran: The Phase 3 trial
Frederick J. Raal Inclisiran: The Phase 3 trial
Play FOURIER trial: Update on subgroup analyses
Peter Sever FOURIER trial: Update on subgroup analyses
Play ODYSSEY OUTCOMES: Update
Andreas M Zeiher ODYSSEY OUTCOMES: Update
Play The new AHA/ACC Treatment Guidelines: Critical appraisal
Henry Ginsberg The new AHA/ACC Treatment Guidelines: Critical appraisal
Play Is it time to upgrade Lp(a) to a therapeutic target in Guidelines?
Børge Nordestgaard Is it time to upgrade Lp(a) to a therapeutic target in Guidelines?
Play ODYSSEY OUTCOMES: Recurrent events, mortality and Lp(a)
Gregory G. Schwartz Michael Szarek ODYSSEY OUTCOMES: Recurrent events, mortality and Lp(a)
Play Lp(a) and CV risk: Insights from the FOURIER trial
Erin Bohula Lp(a) and CV risk: Insights from the FOURIER trial
Play Genetics of Lp(a) and CVD
Anne Tybjaerg-Hansen Genetics of Lp(a) and CVD
Play Do LDL subfractions matter?
John Chapman Do LDL subfractions matter?
Play PCSK9 and the adrenals: how are cholesterol levels protected?
Bo Angelin PCSK9 and the adrenals: how are cholesterol levels protected?
Play Does one plaque characteristic fit all?
Gerard Pasterkamp Does one plaque characteristic fit all?
Play Lp(a) as a cardiovascular risk factor – Is lowering Lp(a) beneficial when LDL is low?
Pia Kamstrup Lp(a) as a cardiovascular risk factor – Is lowering Lp(a) beneficial when LDL is low?
Play Low LDL-C and cognitive function: Benefit or harm?
Francois Mach Low LDL-C and cognitive function: Benefit or harm?
Play Do low LDL-C levels enhance diabetes risk?
Dirk Müller-Wieland Do low LDL-C levels enhance diabetes risk?